Ferrer

Belkins
Ferrer is an international pharmaceutical company, headquartered in Barcelona with a presence in more than 90 countries. Our mission is to advance the wellbeing of society.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TECH

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals | January 06, 2021

news image

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More

BUSINESS INSIGHTS

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos | September 20, 2021

news image

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

RESEARCH

RHYTHM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR OBESITY MED TARGETING GENETIC DEFECTS

Rhythm | December 01, 2020

news image

Stoutness is a significant issue around the world, in any case, for a small amount of patients, hereditary changes instead of propensities are driving the sickness. With its new FDA endorsement for Imcivree, Rhythm Pharmaceuticals is venturing out treating those cases. For a subset of heftiness patients, hereditary transformations leave them with an "voracious appetite," Rhythm CEO David Meeker, M.D., said in a meeting. Beginning stage hereditary illnesses can leave pati...

Read More

BUSINESS INSIGHTS

COEUS HOLDINGS ANNOUNCES PARTNERSHIP WITH INSIGHT CONSULTING GROUP (ICG) TO ADDRESS THE HEALTHCARE INDUSTRY’S CHANGING RESEARCH AND INSIGHT LANDSCAPE

COEUS Holdings | September 18, 2021

news image

COEUS Holdings, LLC, and its subsidiaries, together a leading boutique life sciences technology and consulting firm, today announced that it has entered a partnership with Insight Consulting Group (ICG). The partnership seeks to bridge the gaps between payers, healthcare providers, and consumers by developing insights and strategies that are reflective of today’s integrated needs. The partnership will produce and apply comprehensive insights to inform strategy that could advance access to ...

Read More

PHARMA TECH

Sebela Pharmaceuticals | January 06, 2021

news image

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More

BUSINESS INSIGHTS

Glaukos | September 20, 2021

news image

GLAUKOS ANNOUNCES LICENSING AGREEMENT WITH ATTILLAPS HOLDINGS, INC.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc. under which Attillaps has granted Glaukos a global exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradicatio...

Read More

RESEARCH

Rhythm | December 01, 2020

news image

RHYTHM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR OBESITY MED TARGETING GENETIC DEFECTS

Stoutness is a significant issue around the world, in any case, for a small amount of patients, hereditary changes instead of propensities are driving the sickness. With its new FDA endorsement for Imcivree, Rhythm Pharmaceuticals is venturing out treating those cases. For a subset of heftiness patients, hereditary transformations leave them with an "voracious appetite," Rhythm CEO David Meeker, M.D., said in a meeting. Beginning stage hereditary illnesses can leave pati...

Read More

BUSINESS INSIGHTS

COEUS Holdings | September 18, 2021

news image

COEUS HOLDINGS ANNOUNCES PARTNERSHIP WITH INSIGHT CONSULTING GROUP (ICG) TO ADDRESS THE HEALTHCARE INDUSTRY’S CHANGING RESEARCH AND INSIGHT LANDSCAPE

COEUS Holdings, LLC, and its subsidiaries, together a leading boutique life sciences technology and consulting firm, today announced that it has entered a partnership with Insight Consulting Group (ICG). The partnership seeks to bridge the gaps between payers, healthcare providers, and consumers by developing insights and strategies that are reflective of today’s integrated needs. The partnership will produce and apply comprehensive insights to inform strategy that could advance access to ...

Read More